About Pre-B-cell leukemia transcription factor 4
Pre-B-cell leukemia transcription factor 4 (PBX4) is a protein
from Homo sapiens identified by UniProt accession
Q9BYU1, 374 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | Pre-B-cell leukemia transcription factor 4 |
| UniProt accession | Q9BYU1 |
| Gene | PBX4 |
| Organism | Homo sapiens |
| Length | 374 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (88)
Diseases linked to this target (Open Targets).
- eosinophil count · score 0.31
- body height · score 0.25
- lymphocyte count · score 0.23
- eosinophil percentage of leukocytes · score 0.21
- low density lipoprotein cholesterol measurement · score 0.20
- total cholesterol measurement · score 0.19
- neutrophil percentage of leukocytes · score 0.17
- mathematical ability · score 0.16
- sleep duration · score 0.16
- basophil count · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BYU1-F1 | alphafold | PREDICTED | 72.42 | — |
Amino-acid sequence (374 residues)
MAAPPRPAPS PPAPRRLDTS DVLQQIMAIT DQSLDEAQAR KHALNCHRMK PALFSVLCEI KEKTVVSIRG IQDEDPPDAQ LLRLDNMLLA EGVCRPEKRG RGGAVARAGT ATPGGCPNDN SIEHSDYRAK LSQIRQIYHS ELEKYEQACR EFTTHVTNLL QEQSRMRPVS PKEIERMVGA IHGKFSAIQM QLKQSTCEAV MTLRSRLLDA RRKRRNFSKQ ATEVLNEYFY SHLNNPYPSE EAKEELARKG GLTISQVSNW FGNKRIRYKK NMGKFQEEAT IYTGKTAVDT TEVGVPGNHA SCLSTPSSGS SGPFPLPSAG DAFLTLRTLA SLQPPPGGGC LQSQAQGSWQ GATPQPATAS PAGDPGSINS STSN
Explore Pre-B-cell leukemia transcription factor 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets